At the same time, although currently available selective PDE5 inhibitors have low blood-brain barrier (BBB) permeability, tadalafil and sildenafil have been used in chronic treatments and in a range of AD models, confirming their efficacy in reversing cognitive impairment [10, 207, 211]. This evidence concerns the gene PDE5A and Alzheimer disease.